TWI776882B - 胺吡啶衍生化合物之鹽類、其結晶形及其製備方法 - Google Patents

胺吡啶衍生化合物之鹽類、其結晶形及其製備方法 Download PDF

Info

Publication number
TWI776882B
TWI776882B TW107113234A TW107113234A TWI776882B TW I776882 B TWI776882 B TW I776882B TW 107113234 A TW107113234 A TW 107113234A TW 107113234 A TW107113234 A TW 107113234A TW I776882 B TWI776882 B TW I776882B
Authority
TW
Taiwan
Prior art keywords
crystalline form
mesylate
mesylate salt
organic solvent
formula
Prior art date
Application number
TW107113234A
Other languages
English (en)
Chinese (zh)
Other versions
TW201841910A (zh
Inventor
吳相昊
金鍾均
吳世雄
韓兌東
鄭水龍
李性蘭
金京培
李永成
申優燮
朱賢
姜正基
朴秀民
金東均
Original Assignee
南韓商柳韓洋行股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63857137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI776882(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 南韓商柳韓洋行股份有限公司 filed Critical 南韓商柳韓洋行股份有限公司
Publication of TW201841910A publication Critical patent/TW201841910A/zh
Application granted granted Critical
Publication of TWI776882B publication Critical patent/TWI776882B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW107113234A 2017-04-21 2018-04-18 胺吡啶衍生化合物之鹽類、其結晶形及其製備方法 TWI776882B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
??10-2017-0051687 2017-04-21
KR10-2017-0051687 2017-04-21
KR20170051687 2017-04-21

Publications (2)

Publication Number Publication Date
TW201841910A TW201841910A (zh) 2018-12-01
TWI776882B true TWI776882B (zh) 2022-09-11

Family

ID=63857137

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107113234A TWI776882B (zh) 2017-04-21 2018-04-18 胺吡啶衍生化合物之鹽類、其結晶形及其製備方法

Country Status (22)

Country Link
US (3) US11453656B2 (https=)
EP (1) EP3612529A4 (https=)
JP (2) JP7126514B2 (https=)
KR (3) KR102629654B1 (https=)
CN (1) CN110869367B (https=)
AR (1) AR111469A1 (https=)
AU (2) AU2018256227B2 (https=)
CA (1) CA3059543A1 (https=)
CO (1) CO2019011578A2 (https=)
EA (1) EA201992501A1 (https=)
IL (2) IL270018B (https=)
MA (1) MA49696A (https=)
MX (2) MX392634B (https=)
MY (1) MY201919A (https=)
NZ (1) NZ758443A (https=)
PH (1) PH12019502370A1 (https=)
SA (1) SA519410342B1 (https=)
SG (1) SG11201909615YA (https=)
TW (1) TWI776882B (https=)
UA (1) UA124364C2 (https=)
WO (1) WO2018194356A1 (https=)
ZA (1) ZA201907687B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
FI3658552T3 (fi) 2017-07-28 2023-11-16 Yuhan Corp Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
WO2020125391A1 (zh) * 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
WO2020230091A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
AU2020275272A1 (en) * 2019-05-14 2021-12-02 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
PH12022552076A1 (en) 2020-02-12 2023-11-29 Janssen Biotech Inc TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS
PH12022552454A1 (en) * 2020-04-14 2024-02-05 Janssen Biotech Inc Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
WO2022253261A1 (zh) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160102076A1 (en) * 2014-10-13 2016-04-14 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1698623T3 (pl) 2003-12-25 2015-08-31 Eisai R&D Man Co Ltd Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania
US8048883B2 (en) 2004-02-11 2011-11-01 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
TWI546290B (zh) * 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
MX2012005332A (es) 2009-11-13 2012-10-15 Oscotec Inc Inhibidores de cinasa.
WO2012077136A2 (en) 2010-12-06 2012-06-14 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
CN103702990B (zh) * 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN104540822B (zh) 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
EP3143015B1 (en) 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
KR101794186B1 (ko) 2015-10-30 2017-11-08 한국기술교육대학교 산학협력단 전기자동차용 급전장치
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160102076A1 (en) * 2014-10-13 2016-04-14 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities

Also Published As

Publication number Publication date
CN110869367A (zh) 2020-03-06
JP2022166179A (ja) 2022-11-01
BR112019021868A2 (pt) 2020-05-26
JP2020517611A (ja) 2020-06-18
KR102629654B1 (ko) 2024-01-29
KR20250111074A (ko) 2025-07-22
EA201992501A1 (ru) 2020-02-18
US11981659B2 (en) 2024-05-14
IL270018B (en) 2022-08-01
AR111469A1 (es) 2019-07-17
JP7126514B2 (ja) 2022-08-26
MA49696A (fr) 2020-06-03
KR20180118535A (ko) 2018-10-31
JP7390444B2 (ja) 2023-12-01
IL270018A (https=) 2019-12-31
IL294666B1 (en) 2024-01-01
MX392634B (es) 2025-03-24
US20210139461A1 (en) 2021-05-13
KR20230175161A (ko) 2023-12-29
MY201919A (en) 2024-03-23
TW201841910A (zh) 2018-12-01
US20240279203A1 (en) 2024-08-22
CO2019011578A2 (es) 2020-02-28
WO2018194356A1 (en) 2018-10-25
CA3059543A1 (en) 2018-10-25
IL294666B2 (en) 2024-05-01
EP3612529A4 (en) 2020-11-18
UA124364C2 (uk) 2021-09-01
US11453656B2 (en) 2022-09-27
MX2022006357A (es) 2022-06-23
PH12019502370A1 (en) 2020-07-13
AU2018256227B2 (en) 2022-03-03
IL294666A (en) 2022-09-01
AU2022203486A1 (en) 2022-06-09
US12428401B2 (en) 2025-09-30
US20230021395A1 (en) 2023-01-26
EP3612529A1 (en) 2020-02-26
AU2022203486B2 (en) 2024-06-06
CN110869367B (zh) 2023-09-15
ZA201907687B (en) 2023-04-26
SG11201909615YA (en) 2019-11-28
NZ758443A (en) 2023-03-31
AU2018256227A1 (en) 2019-10-31
SA519410342B1 (ar) 2023-02-09
KR102835717B1 (ko) 2025-07-18

Similar Documents

Publication Publication Date Title
TWI776882B (zh) 胺吡啶衍生化合物之鹽類、其結晶形及其製備方法
KR102662358B1 (ko) Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
JP2011515370A (ja) ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態
US9388165B2 (en) Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase
TW201236684A (en) Pharmaceutically acceptable salts of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation process and pharmaceutical use there of
JP6920467B2 (ja) ピリミジン誘導体化合物、その光学異性体、またはその薬学的に許容される塩、及びそれを有効成分として含むｔｙｒｏ３関連疾患の予防または治療用組成物
CN112119074A (zh) Egfr抑制剂
KR101929725B1 (ko) 의학적 적용을 위한 3-(1,2,4-트리아졸로[4,3-a]피리딘-3-일에티닐)-4-메틸-N-(4-((4-메틸피페라진-1-일)메틸)-3-트리플루오로메틸페닐)벤즈아미드의 신규 결정질 염 형태
KR102382641B1 (ko) 신규한 tyro 3 저해 화합물, 이의 제조방법, 및 이를 유효성분으로 함유하는 tyro 3 관련 질환의 예방 또는 치료용 약학적 조성물
CN117396463A (zh) 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法和含有其作为活性成分的药物组合物
HK40025158B (zh) 氨基吡啶衍生物化合物的盐、其结晶形式、以及用於制备它们的方法
HK40025158A (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
EA041089B1 (ru) Соль соединения производного аминопиридина, ее кристаллическая форма и способ получения
CN114805301B (zh) 2,4-二芳氨基嘧啶类化合物及其制备方法和应用
BR112019021868B1 (pt) Sal de mesilato de n-(5-(4-(4-((dimetilamino)metil)-3- fenil-1h-pirazol-1-il) pirimidina-2-ilamino)-4-metóxi-2- morfolinofenil)acrilamida, seu processo de preparação, seus usos, e composição farmacêutica
HK40037665A (en) Egfr inhibitors
BR122023014950B1 (pt) Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent